Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.

 Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire
                          Incline Therapeutics, Inc.

PR Newswire

SAN DIEGO, Calif., Dec. 12, 2012

SAN DIEGO, Calif., Dec. 12, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc.
(Nasdaq: CADX), a biopharmaceutical company focused on acquiring,
in-licensing, developing and commercializing proprietary products principally
for use in the hospital setting, announced today that it has entered into an
agreement to terminate its exclusive option to acquire privately-held Incline
Therapeutics, Inc., or Incline.

Under the waiver, consent and option termination agreement signed by Cadence
and Incline, upon the closing of the proposed acquisition of Incline by The
Medicines Company (Nasdaq: MDCO), Cadence would receive a payment of
approximately $13 million to buy-out Cadence's interest in, and terminate
Cadence's rights with respect to, the option agreement. Additionally, Cadence
would receive approximately $1.5 million related to the purchase by The
Medicines Company of the shares of Incline common stock held by Cadence,
subject to adjustment, and, potentially, a pro rata share of future milestone
payments. The acquisition of Incline by The Medicines Company is subject to
the satisfaction or waiver of customary closing conditions, and is currently
expected to close in January, 2013.

"The sale of our Incline option provides Cadence with non-dilutive capital and
a solid return on our original investment," said Ted Schroeder, President and
CEO of Cadence. "We're excited about the continued growth in sales of OFIRMEV,
and believe that today's announcement provides us with further flexibility to
focus on other drivers of near term revenue growth."

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring,
in-licensing, developing and commercializing proprietary products principally
for use in the hospital setting. The current version of Cadence
Pharmaceuticals' corporate overview may be viewed on the Investors page of under "Events & Presentations" by selecting "Corporate

About OFIRMEV^® (Acetaminophen) Injection

OFIRMEV (acetaminophen) injection (1000 mg / 100 mL, 10 mg / mL; for
intravenous use only), Cadence Pharmaceuticals' proprietary intravenous
formulation of acetaminophen, is indicated for the management of mild to
moderate pain, the management of moderate to severe pain with adjunctive
opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was
based on data from clinical trials in approximately 1,020 adult and 355
pediatric patients. These trials included two studies evaluating the safety
and effectiveness of OFIRMEV in the treatment of pain, and one study
evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for
the treatment of acute pain and fever has not been studied in pediatric
patients less than 2 years of age.

Important Safety Information

Do not exceed the maximum recommended daily dose of acetaminophen.
Administration of acetaminophen by any route in doses higher than recommended
may result in hepatic injury, including the risk of severe hepatotoxicity and
death. OFIRMEV is contraindicated in patients with severe hepatic impairment,
severe active liver disease or with known hypersensitivity to acetaminophen or
to any of the excipients in the formulation. Acetaminophen should be used with
caution in patients with the following conditions: hepatic impairment or
active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia,
or severe renal impairment.OFIRMEV should be administered only as a 15-minute
intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated
with allergy or hypersensitivity occur. Do not use in patients with
acetaminophen allergy. The most common adverse reactions in patients treated
with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients
and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in
pediatric patients. The antipyretic effects of OFIRMEV may mask fever in
patients treated for post-surgical pain.

For more information, please see the complete OFIRMEV Prescribing Information,
available at or

Forward-Looking Statements

Statements included in this press release that are not a description of
historical facts are forward-looking statements. Words such as "plans,"
"believes," "expects," "anticipates," and "will," and similar expressions, are
intended to identify forward-looking statements, and are based on Cadence's
current beliefs and expectations. Such statements include, without limitation,
statements regarding the anticipated closing date for the acquisition of
Incline by The Medicines Company, the potential for Cadence to receive
payments related to that transaction, and the potential for continued growth
in sales of OFIRMEV, which speak only as of the date hereof. Cadence's actual
future results may differ materially from Cadence's current expectations due
to the risks and uncertainties inherent in its business. These risks include,
but are not limited to: the risk that the closing of the Incline acquisition
may be delayed or may not occur at all; and Cadence's dependence on the
successful commercialization of OFIRMEV, which is Cadence's only product; and
other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic
reports and other filings made with the SEC from time to time. All
forward-looking statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of Section 21E of
the Private Securities Litigation Reform Act of 1995, and the company
undertakes no obligation to revise or update this press release to reflect
events or circumstances after the date hereof.

Cadence^® and OFIRMEV^® are trademarks of Cadence Pharmaceuticals, Inc.

Contact: William R. LaRue             Kelli France
         SVP & Chief Financial Officer Media Relations
         Cadence Pharmaceuticals, Inc. WCG
         Phone: 858-436-1400           Phone: 415-946-1076

SOURCE Cadence Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.